Infinity Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Infinity Pharmaceuticals, Inc. (INFI) is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize novel small molecule drugs targeting cancer through immuno-oncology mechanisms; its lead product candidate is eganelisib (IPI-549), an oral, selective inhibitor of phosphoinositide 3-kinase gamma (PI3K-gamma) designed to reprogram immunosuppressive macrophages in the tumor microenvironment, evaluated in Phase 2 clinical trials including combinations with checkpoint inhibitors such as pembrolizumab for head and neck squamous cell carcinoma, triple-negative breast cancer, urothelial cancer, and renal cell carcinoma, and in earlier studies like MARIO-1, MARIO-275, and MARIO-3 for solid tumors. The company previously advanced other candidates including duvelisib (PI3K-delta/gamma inhibitor) for hematologic malignancies and IPI-926 (Hedgehog pathway inhibitor), though most historical programs such as IPI-493 and others have been discontinued. Infinity operates primarily in the United States with a focus on oncology therapeutics for patients with advanced solid tumors and blood cancers. Founded in 1995 and headquartered in Cambridge, Massachusetts, Infinity has historically maintained strategic alliances including with Verastem for duvelisib commercialization rights, AbbVie (formerly Intellikine) for PI3K inhibitors, and PellePharm for hedgehog inhibitors; in recent years, it pursued a definitive merger agreement announced in February 2023 with MEI Pharma, Inc. to combine oncology pipelines centered on eganelisib, voruciclib, and ME-344, providing funding into mid-2025, but terminated the deal in July 2023 after MEI shareholders rejected it amid competing takeover bids from activist investors. Following merger termination, Infinity filed for voluntary Chapter 11 bankruptcy reorganization on September 29, 2023, in the U.S. Bankruptcy Court for the District of Delaware, approved as a Chapter 11 liquidation plan on March 7, 2024, with substantially all assets acquired by an undisclosed healthcare investment firm, ceasing normal operations and winding down amid cash constraints and going concern doubts. Its common stock now trades over-the-counter as INFIQ.
Infinitum Amends Proposed Share Consolidation Ratio
INFI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities Class Action – INFI
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
INFI IMPORTANT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities Class Action - INFI
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
INFINITY DEADLINE REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their Options
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
ROSEN, A LONGSTANDING LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFI
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm